Government · 2 deals
Every published round Biomedical Advanced Research and Development Authority took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Vaxxas | Series D+ | Aug 2025 | $49m | Participant | Startup Daily (23 Dec 2025), SmartCompany (23 Dec 2025), Startup Daily (14 Oct 2025), Cut Through Venture, Startup Daily (29 Aug 2025), SmartCompany (29 Aug 2025), Startup Daily (26 Aug 2025), Business News Australia | |
| Vaxxas | Grant | 14 Jan 2025 | $3.2m | Lead | Business News Australia, Brandon BioCatalyst (18 Feb 2025), Brandon Capital (18 Feb 2025), @AuManufacturing (23 Jan 2025), @AuManufacturing (20 Jan 2025), Brandon BioCatalyst (14 Jan 2025), Brandon Capital (14 Jan 2025) |
Companies Biomedical Advanced Research and Development Authority has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Vaxxas | Biotech/MedTech company | 14 Jan 2025, Grant | 2 | 1 |
Fund closes reported for Biomedical Advanced Research and Development Authority, as distinct from the investments it has made.
Companies Biomedical Advanced Research and Development Authority has backed that another company then bought. An exit for the holding, not a deal Biomedical Advanced Research and Development Authority did.
Stories naming Biomedical Advanced Research and Development Authority. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of short industry items: Element 25 and Vaxxas win US government grants, Orthocell gets an R&D refund, Convergence Medical completes its Series A, and Monique Conheady takes a Hysata board seat.
Also Startup Daily
Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia
Vaxxas, a Brisbane biotech, has taken a worldwide licence from the US NIH to an RSV antigen candidate, aiming to advance it toward a Phase I study; another trial runs with BARDA funding.
Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Vaxxas has appointed 23-year Pfizer veteran Dr Rochelle Chaiken as chief medical officer; the announcement also recaps the vaccine-patch company's early backing by OneVentures, Brandon Capital and others.
Vaxxas has begun an Australian Phase I trial of its needle-free influenza vaccine patch. The article also recalls the company's founding equity financing led by OneVentures with Brandon Capital Partners and other co-investors.
Vaxxas partners with CEPI, which will fund preclinical testing of its needle-free vaccine patch for mRNA vaccines, work that could remove cold-storage needs and widen global access to such vaccines.
Also Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing
Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.
Also OneVentures portfolio·Brandon Capital portfolio·@AuManufacturing·SmartCompany·Techboard·@AuManufacturing
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch, built on a University of Texas at Austin candidate; the article also recalls the company's early financings led by OneVentures.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.